Showing results (421-430 of 601) with videos related to
Sort By:
Pageof 61
Multiple Sclerosis (Houndmills, Basingstoke, England)|March 23, 2016
The EDSS-Plus, an improved endpoint for disability progression in secondary progressive multiple sclerosisDiego Cadavid, Jeffrey A Cohen, Mark S Freedman, et al.Archives of Neurology|November 11, 2009
Magnetic resonance imaging predictors of conversion to multiple sclerosis in the BENEFIT studyBastiaan Moraal, Christoph Pohl, Bernard M J Uitdehaag, et al.Annals of Neurology|February 26, 2005
Phenotypes of the N88S Berardinelli-Seip congenital lipodystrophy 2 mutationMichaela Auer-Grumbach, Beate Schlotter-Weigel, Hanns Lochmüller, et al.Frontiers in Neurology|July 22, 2017
Development and Validation of an Enzyme-Linked Immunosorbent Assay for the Detection of Binding Anti-Drug Antibodies against Interferon BetaKathleen Ingenhoven, Daniel Kramer, Poul Erik Jensen, et al.Muscle & Nerve|March 5, 2009
Electrophysiology in chronic inflammatory demyelinating polyneuropathy with IGIVVera Bril, Hans Katzberg, Peter Donofrio, et al.Journal of Neurology, Neurosurgery, and Psychiatry|May 10, 2024
Efficacy, safety and tolerability of rozanolixizumab in patients with chronic inflammatory demyelinating polyradiculoneuropathy: a randomised, subject-blind, investigator-blind, placebo-controlled, phase 2a trial and open-label extension studyLuis Querol, Jérôme De Sèze, Tina Dysgaard, et al.Journal of Neuroinflammation|October 26, 2016
Inositol 1,4,5-trisphosphate receptor type 1 autoantibodies in paraneoplastic and non-paraneoplastic peripheral neuropathySven Jarius, Marius Ringelstein, Jürgen Haas, et al.Neurology|October 14, 2016
Alemtuzumab improves preexisting disability in active relapsing-remitting MS patientsGavin Giovannoni, Jeffrey A Cohen, Alasdair J Coles, et al.Multiple Sclerosis (Houndmills, Basingstoke, England)|January 7, 2022
Body mass index as a predictor of MS activity and progression among participants in BENEFITJuan Manuel Escobar, Marianna Cortese, Gilles Edan, et al.The Lancet. Neurology|September 15, 2009
Long-term effect of early treatment with interferon beta-1b after a first clinical event suggestive of multiple sclerosis: 5-year active treatment extension of the phase 3 BENEFIT trialLudwig Kappos, Mark S Freedman, Chris H Polman, et al.Pageof 61